PDCD1 and malignant colon neoplasm: Another studies revealed that CpG-ODN can revert resistence to PD-1 blockade therapy by expending CD8+ T cells in colon cancer animal model, enhances the efficacy of anti-PD-1 in head and neck cancer animal model (198, 199).